D
Deargen
Biotech & Life Sciences · Daejeon, South Korea · Founded 2016
AI-powered drug design biotech company advancing treatments for rare and intractable diseases through genome data analysis and molecule optimization MoreLess
Deargen Inc. is a biotechnology company that leverages advanced Artificial Intelligence (AI) to revolutionize the development of new drugs, particularly for rare and intractable diseases. The company operates in the pharmaceutical and healthcare markets, focusing on integrating AI with drug discovery processes to enhance efficiency and precision. Deargen's AI platform, Dr.UG, utilizes deep learning technology to analyze genome data, predict biomarkers, and select and optimize molecules for drug development. This approach allows Deargen to identify new disease targets and design small molecules for precision medicine.
Deargen serves pharmaceutical companies, research institutions, and healthcare providers who are looking for innovative solutions to accelerate drug discovery and development. The company's business model is based on partnerships and collaborations, both corporate and scientific, to co-develop new treatments and bring them to market. Revenue is generated through these partnerships, licensing agreements, and potentially through the commercialization of successful drug candidates.
Keywords: AI-powered, drug design, biotechnology, rare diseases, genome analysis, biomarker prediction, molecule optimization, precision medicine, pharmaceutical partnerships, deep learning.
Company overview
Deargen company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Daejeon, South Korea
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 69.0
Valuation & funding
Deargen funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2022 | $17M | $68M | TS Investment · Korea Development Bank · Hana Ventures | — |
| SEEDEquity / VC | Nov 2020 | $2.5M | $10M | Hana Ventures · TS Investment · Amyloid Solution | — |
| OtherOther financing | Nov 2018 | $0 | — | Undisclosed | — |
| SPINOUT✓Other financing | Dec 2016 | $0 | — | Emory University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 11 |
| 2025 | 12 |
| 2024 | 18 |
| 2023 | 36 |
| 2022 | 45 |
Growth signals
Deargen website traffic
Latest recorded traffic for Deargen is 2.5K monthly website visits, up 19% over the last three months. Deargen's team declined 8.3% over the past year.
Comparisons
Deargen compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Deargen's talent
Source: Dealroom Talent Intelligence.
Investors
5 investors on Deargen's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Deargen has talent and traffic
team presence
In the news
Latest news about Deargen
Recent press, funding announcements, and product moves mentioning Deargen — open to read from the original sources.
Market sentiment
What the market is saying about Deargen
An AI-synthesized read of the highest-engagement posts about Deargen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Deargen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.